
    
      This is a two-part study where Part 1 will assess the test/retest variability of the ligand
      ([11C]AS2471907). Part 2 will assess the level and time-course of enzyme occupancy following
      ASP3662 dosing. Subjects will be confined to the clinic for up to 2 days.
    
  